<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="178">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04376788</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU P22/2020</org_study_id>
    <nct_id>NCT04376788</nct_id>
  </id_info>
  <brief_title>Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19</brief_title>
  <acronym>COVID-19</acronym>
  <official_title>Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to introduce way for treatment of patients with severe COVID-19
      disease with respiratory complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Tools AND/ OR procedure

      The patients were subjected to the following:

      Clinical parameters:

      Complete history taking and thorough clinical examination

        1. Laboratory parameters:

        2. CBC with differential counts.

        3. Reticulocytic count.

        4. Blood film for shistocytes.

        5. Serum ferritin and transferrin saturation.

        6. D dimer.

        7. Liver function tests, kidney function tests, electrolytes.

        8. ESR.

        9. CRP.

       10. LDH.

       11. Viral markers (HCV Ab, HBsV AG, HIV Ab).

       12. ADAM'S 13 assays.

       13. Serum soluble CD 25.

      Other investigations:

        1. Chest X ray.

        2. Pelviabdominal US.

        3. CT chest.

        4. ECG.

        5. Echocardiography

      The patients will be divided into three groups, each group formed of 5 patients with severe
      COVID-19 or on mechanical ventilator receiving standard of care All the groups matched
      regarding age, sex and the severity of the disease.

      Group I:

      Will receive exchange transfusion by venesection of 500cc blood with good replacement of one
      unit packed washed RBCs daily for 3 days according to daily clinical and investigational
      follow up

      Group II Will receive IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from
      convalescent matching single patient by plasma extractor machine for 3 days according to
      daily clinical and investigational follow up.

      Group III Will receive exchange transfusion by venesection of 500cc blood with good
      replacement of one unit packed washed RBCs and IV methylene blue 1 mg/kg IV over 30 minutes
      with 200 CC plasma from convalescent matching single patient by plasma extractor machine for
      3 days according to daily clinical and investigational follow up.

      N.B.: Convalescent plasma and regular blood will be taken from ministry of health after
      administrative approval All groups will receive

        1. Low dose anticoagulant (LMWH 1 mg/kg/day).

        2. Steroid (methyl prednisone 1 mg/ kg IV daily and according to patients' condition and
           presence of complications like hemophagocytosis).

        3. All allergic precautions if needed like antihistaminics , epinephrine and steroid.

      Close monitoring for:

        1. Allergic reactions.

        2. ECG changes daily.

        3. Volume overload.

        4. Complications of other comorbidities like DM or HTN.

        5. Liver function and kidney function and organ dysfunction daily.

      Terms of discontinuation:

      Deterioration of clinical condition or organ functions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group I:
Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs daily for 3 days according to daily clinical and investigational follow up
Group II Will receive IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up.
Group III Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs and IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement of condition</measure>
    <time_frame>three to five days days</time_frame>
    <description>improvement of general condition of the patients as the ventilator parameters and serum level of ferritin , D dimer, CBC, oxygen level in blood and patient o2 saturation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in organs function with PFS and OS</measure>
    <time_frame>0ne month</time_frame>
    <description>change in the liver , kidney function and change in ferritin level with normal D Dimer</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Exchange transfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs daily for 3 days according to daily clinical and investigational follow up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylene blue with plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exchange transfusion and methylene blue with plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs and IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>exchange blood transfusion from normal donor</intervention_name>
    <description>IV method</description>
    <arm_group_label>Exchange transfusion</arm_group_label>
    <arm_group_label>Exchange transfusion and methylene blue with plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>plasma from convalescent patients with COVID-19</intervention_name>
    <description>IV method</description>
    <arm_group_label>Exchange transfusion and methylene blue with plasma</arm_group_label>
    <arm_group_label>Methylene blue with plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylene Blue 5 MG/ML</intervention_name>
    <description>IV method</description>
    <arm_group_label>Exchange transfusion and methylene blue with plasma</arm_group_label>
    <arm_group_label>Methylene blue with plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients are 18 years old or above.

          2. Inpatients diagnosed as severe COVID - 19 disease according to WHO criteria.

          3. CT chest with extensive lung disease (ground-glass and consolidative pulmonary
             opacities).

          4. O2 saturation less than 93% resting.

          5. Respiratory rate equal or more than 30 per minute.

        Exclusion Criteria:

          1. Patients with pregnancy and lactation.

          2. Renal failure and heart failure.

          3. Contraindication for plasma or blood transfusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed M Moussa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayman I Tharwat, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed M Moussa, MD</last_name>
    <phone>+201001553744</phone>
    <email>drmohamed_metwali1@med.asu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Essam A Hassan, MD</last_name>
    <phone>+201001839394</phone>
    <email>essam.abdelwahed@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <zip>11556</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed M Moussa, MD</last_name>
      <phone>+201001839394</phone>
      <email>drmohamed_metwali1@med.asu.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Essam A Hassan, MD</last_name>
      <phone>+201001939394</phone>
      <email>essam.abdelwahed@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mohamed M Moussa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Essam A Hassan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ayman I Tharwat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Chang, Lin M, Wei L, Xie L, Zhu G, Dela Cruz CS, Sharma L. Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. JAMA. 2020 Mar 17;323(11):1092-1093. doi: 10.1001/jama.2020.1623.</citation>
    <PMID>32031568</PMID>
  </reference>
  <reference>
    <citation>Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, Zimmer T, Thiel V, Janke C, Guggemos W, Seilmaier M, Drosten C, Vollmar P, Zwirglmaier K, Zange S, WÃ¶lfel R, Hoelscher M. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med. 2020 Mar 5;382(10):970-971. doi: 10.1056/NEJMc2001468. Epub 2020 Jan 30.</citation>
    <PMID>32003551</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 1, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mohamed Mahmoud Moussa</investigator_full_name>
    <investigator_title>Professor Of Internal Medicine and Hematology -BMT</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Exchange transfusion</keyword>
  <keyword>Methylene blue</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

